ValuEngine cut shares of Athenex (NASDAQ:ATNX) from a buy rating to a hold rating in a report published on Tuesday.

ATNX has been the subject of a number of other research reports. BidaskClub cut Athenex from a strong-buy rating to a buy rating in a report on Thursday, April 19th. Zacks Investment Research cut Athenex from a buy rating to a hold rating in a report on Wednesday, May 30th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $26.71.

Shares of Athenex stock opened at $17.29 on Tuesday. Athenex has a 12 month low of $13.28 and a 12 month high of $20.90. The company has a market cap of $1.17 billion, a price-to-earnings ratio of -7.45 and a beta of -1.44.

Athenex (NASDAQ:ATNX) last announced its earnings results on Tuesday, August 14th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.10). Athenex had a negative net margin of 136.72% and a negative return on equity of 75.45%. The firm had revenue of $11.57 million for the quarter. equities research analysts expect that Athenex will post -1.36 EPS for the current fiscal year.

In other news, Director Song-Yi Zhang sold 9,592 shares of the company’s stock in a transaction that occurred on Friday, May 25th. The stock was sold at an average price of $16.61, for a total value of $159,323.12. Following the completion of the sale, the director now directly owns 4,000 shares in the company, valued at $66,440. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Sheldon Trainor-Degirolamo sold 31,633 shares of the company’s stock in a transaction that occurred on Monday, June 4th. The shares were sold at an average price of $16.81, for a total value of $531,750.73. The disclosure for this sale can be found here. Insiders sold 289,743 shares of company stock valued at $4,828,490 over the last 90 days. Company insiders own 29.50% of the company’s stock.

Several hedge funds have recently bought and sold shares of the company. MetLife Investment Advisors LLC purchased a new stake in shares of Athenex in the second quarter valued at approximately $376,000. Metropolitan Life Insurance Co. NY purchased a new stake in shares of Athenex in the second quarter valued at approximately $266,000. Bank of America Corp DE grew its position in shares of Athenex by 34.4% in the second quarter. Bank of America Corp DE now owns 56,822 shares of the company’s stock valued at $1,060,000 after purchasing an additional 14,530 shares in the last quarter. Voya Investment Management LLC purchased a new stake in shares of Athenex in the second quarter valued at approximately $294,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Athenex in the second quarter valued at approximately $2,258,000. Institutional investors and hedge funds own 17.30% of the company’s stock.

About Athenex

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.

Further Reading: What kind of dividend yield to CEF’s pay?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.